Andrew Hollman Meyer, Chief Business Officer at Janux Therapeutics, Inc. (JANX), sold 33,330 shares at $30.06 ($1.0M) on 2025-10-28, disclosed to the SEC on 2025-10-30.
Scheduled sale ($1.0M) by Chief Business Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $30.06 | 16,665 | $501K | 50.0% |
| 2 | $30.06 | 16,665 | $501K | 50.0% |
| Total | $30.06 avg | 33,330 | $1.0M | 100% |
| Filing → |
| JANX | SELL | 2025-11-14 | $100K | — | Filing → |
| JANX | SELL | 2025-05-02 | $200K | — | Filing → |
| JANX | SELL | 2025-04-23 | $100K | — | Filing → |